• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

    5/23/25 4:05:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MOVE alert in real time by email

    PLEASANTON, Calif., May 23, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that it received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Form 10-Q was due on May 15, 2025.

    (PRNewsfoto/Movano)

    The Notice states that the Company has 60 calendar days, or until July 21, 2025, to submit a plan to regain compliance with the Listing Rule (the "Plan"). If Nasdaq accepts the Company's Plan to regain compliance, then Nasdaq may grant the Company up to 180 calendar days from the Form 10-Q filing due date, or until November 11, 2025, to file its Form 10-Q to regain compliance. If Nasdaq does not accept the Company's Plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel.

    About Movano Health

    Founded in 2018, Movano Inc. (NASDAQ:MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.

    Movano Health's proprietary technologies and wearable medical device solutions enable the use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit https://movanohealth.com/. 

    Forward Looking Statements

    This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements relating to the Company's plan to regain compliance with Nasdaq's rules and the timing thereof. Actual results could differ materially from those expressed in or implied by the forward-looking statements due to a number of risks and uncertainties, including but not limited to the timing of the Company's submission of a compliance plan, Nasdaq's acceptance of any such plan, and the duration of any extension that may be granted by Nasdaq; the potential inability to meet Nasdaq's requirements; uncertainties associated with the Company's preparation of the Delinquent Filing; and the possibility of additional delays in the filing of the delinquent filing and the Company's other SEC filings. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/movano-health-receives-notification-of-deficiency-from-nasdaq-related-to-delayed-filing-of-quarterly-report-on-form-10-q-302464510.html

    SOURCE Movano

    Get the next $MOVE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MOVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MOVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CORVEX, INC. ANNOUNCES ADDITIONAL DETAILS OF SPECIAL 35.8% STOCK DIVIDEND FOR SHAREHOLDERS OF RECORD ON MARCH 30, 2026

    ARLINGTON, Va., March 24, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE) ("Corvex" or the "Company") today announced additional details regarding the special 35.8% stock dividend (the "Stock Dividend") previously announced on March 19, 2026.  Each stockholder of record as of the close of business on March 30, 2026 will be entitled to receive a 35.8% stock dividend at no cost and with no action required on the part of the stockholder.For example, a stockholder holding 10,000 shares of Corvex common stock, par value $0.0001 per share (the "Common Stock") as of the close of tradin

    3/24/26 8:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Launches Secure Model Weights, Delivering Hardware-Enforced Protection for AI Inference on Third-Party Infrastructure

    Patent-pending solution gives AI model builders and security-conscious enterprises cryptographic, owner-controlled key custody, protecting model weights from even the infrastructure providerARLINGTON, Va., March 12, 2026 /PRNewswire/ -- Corvex, Inc., an engineering-led AI infrastructure platform, today announced the early availability of Corvex Secure Model Weights, a patent-pending solution that enables AI model builders and enterprises to deploy inference workloads on third-party GPU infrastructure without exposing their model weights, which can be their most valuable intellectual property.

    3/12/26 5:53:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Among the First Companies to Achieve Verified Production Deployment of Confidential Computing for AI on NVIDIA HGX™ B200 Systems

    Encrypted NVIDIA NVSwitch and NVIDIA NVLink fabric protect data in use at runtime, with CPU and GPU remote attestationNear native performance enables secure AI without compromising production scaleARLINGTON, Va., March 3, 2026 /PRNewswire/ -- Corvex, Inc., an AI cloud computing company specializing in GPU-accelerated infrastructure for AI workloads, today announced it has completed and verified the production deployment of confidential computing on NVIDIA HGX B200 systems. The deployment validates encrypted GPU-to-GPU communication across NVIDIA NVSwitch and NVIDIA NVLink fabric

    3/3/26 8:30:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Demsey Seth

    3 - Corvex, Inc. (0001734750) (Issuer)

    3/23/26 5:35:50 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Fairbairn Emily

    4 - Movano Inc. (0001734750) (Issuer)

    3/19/26 5:07:19 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Cogan Jeremy

    4 - Movano Inc. (0001734750) (Issuer)

    3/19/26 5:07:01 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    SEC Filings

    View All

    $MOVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Movano Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Movano Inc. (0001734750) (Filer)

    3/19/26 4:15:09 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form RW filed by Movano Inc.

    RW - Movano Inc. (0001734750) (Filer)

    3/19/26 9:19:29 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 425 filed by Movano Inc.

    425 - Movano Inc. (0001734750) (Subject)

    3/13/26 8:57:45 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Caballero Ruben bought 22,000 shares, increasing direct ownership by 38% to 80,200 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/12/24 4:30:19 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fairbairn Emily bought 4,690,000 shares (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:08 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cogan Jeremy bought 45,000 shares, increasing direct ownership by 6% to 780,649 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:14 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Financials

    Live finance-specific insights

    View All

    CORVEX, INC. ANNOUNCES ADDITIONAL DETAILS OF SPECIAL 35.8% STOCK DIVIDEND FOR SHAREHOLDERS OF RECORD ON MARCH 30, 2026

    ARLINGTON, Va., March 24, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE) ("Corvex" or the "Company") today announced additional details regarding the special 35.8% stock dividend (the "Stock Dividend") previously announced on March 19, 2026.  Each stockholder of record as of the close of business on March 30, 2026 will be entitled to receive a 35.8% stock dividend at no cost and with no action required on the part of the stockholder.For example, a stockholder holding 10,000 shares of Corvex common stock, par value $0.0001 per share (the "Common Stock") as of the close of tradin

    3/24/26 8:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Reports Q3 2024 Financial Results and Provides Business Update

    Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto

    11/14/24 4:05:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Reports Q2 2024 Financial Results and Provides Business Update

    Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device

    8/14/24 4:05:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    4/10/24 4:39:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Movano Inc. (Amendment)

    SC 13G/A - Movano Inc. (0001734750) (Subject)

    4/9/24 5:41:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    2/4/22 4:20:05 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care